Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
PTC Therapeutics ( (PTCT) ) has issued an announcement.
PTC Therapeutics announced its financial performance and strategic milestones for 2024, showcasing unaudited revenues of approximately $814 million, surpassing guidance. Key achievements include successful regulatory applications, a significant license agreement with Novartis for the PTC518 program, and strong cash reserves to drive future growth. The company expects 2025 revenues between $600 million and $800 million, with specific plans for product launches and royalty revenues. PTC’s strategic moves position it for sustained growth in the rare disorders market, with several regulatory and clinical milestones anticipated in 2025.
More about PTC Therapeutics
PTC Therapeutics, Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines for rare disorders. The company emphasizes innovation in creating new therapies and has a diverse pipeline of transformative medicines.
YTD Price Performance: -4.23%
Average Trading Volume: 744,299
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.39B
See more data about PTCT stock on TipRanks’ Stock Analysis page.
